Resultados de la búsqueda 251-260 of 14333 for Severe hyperkalaemia

1. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

2. Hematología - Ensayos clínicos - Mayo Clinic

   Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring ...

3. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

4. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

5. Hematología - Ensayos clínicos - Mayo Clinic

   ... Chronic Lymphocytic Leukemia. Rochester, Minn. This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab ...

6. Hematología - Ensayos clínicos - Mayo Clinic

   This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or ...

7. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

8. Hematología - Ensayos clínicos - Mayo Clinic

   Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring ...

9. Hematología - Ensayos clínicos - Mayo Clinic

   Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring ...

10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...